{
  "tenant_id": "digital-health-startup",
  "org_id": "clinical-dev",
  "project_id": "mindfulmoods-pivotal",
  "product_id": "mindfulmoods-v1",
  "environment": "prod",
  "domain": "Clinical Development",
  "use_case": {
    "code": "UC_CD_001",
    "title": "DTx Clinical Endpoint Selection & Validation",
    "summary": "Structured workflow guiding cross-functional teams to select, validate, and document primary and secondary clinical endpoints for digital therapeutic trials aligned with FDA precedent, patient priorities, and commercial value.",
    "complexity": "Advanced",
    "version": "v3.0",
    "status": "approved",
    "tags": ["endpoint", "clinical", "FDA", "PROMPTS", "FORGE"],
    "therapeutic_area": "Behavioral Health",
    "indication": "Major Depressive Disorder (MDD)",
    "phase": "Pivotal",
    "regulatory_references": [
      "FDA PRO Guidance (2009)",
      "FDA Digital Health Center of Excellence Resources",
      "21 CFR Part 11"
    ],
    "compliance_flags": {"hipaa": true, "gdpr": true, "part11": true, "gxp": "device"},
    "data_classification": {"phi": false, "pii": true, "sensitivity": "medium"},
    "owners": ["role:CMO"],
    "reviewers": ["role:VPCLIN", "role:REGDIR"],
    "approvers": ["role:Head_Medical_Affairs"],
    "change_log": [
      {"at": "2025-10-10T00:00:00Z", "by": "system", "note": "Version 3.0 approved"}
    ],
    "workflows": [
      {
        "name": "Endpoint Selection & Validation Workflow",
        "description": "Five-phase workflow: foundation, research, identification, validation, and decision—producing a regulatory-ready endpoint strategy for digital therapeutics.",
        "sla": {"target_duration_hours": 4, "quality_gate_pass_rate": 0.9},
        "templates": {
          "documents": [
            {"name": "Endpoint Decision Matrix", "template_id": "matrix_v1", "link": "drive://templates/endpoint_matrix.docx"},
            {"name": "Regulatory Risk Assessment", "template_id": "regrisk_v1", "link": "drive://templates/reg_risk.docx"}
          ],
          "prompts": [{"name": "Clinical_Context_Definition", "template_id": "prompt_uc01_1_1_1"}],
          "reports": [{"name": "Endpoint Selection Report", "template_id": "endpoint_report_v1"}]
        },
        "rag_sources": [
          {"id": "FDA_PRO_2009", "title": "FDA PRO Guidance", "link": "https://www.fda.gov/media/77832/download", "kind": "guidance"},
          {"id": "Somryst_DEN190033", "title": "Somryst De Novo Summary", "link": "https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN190033.pdf", "kind": "precedent"}
        ],
        "tasks": [
          {
            "code": "T1.1",
            "title": "Define Clinical Context",
            "objective": "Establish clinical problem, target population, and therapeutic mechanism.",
            "duration_estimate_minutes": 30,
            "state": "done",
            "assignees": ["role:CMO", "role:PATADV"],
            "agents": ["P01_CMO", "P10_PATADV"],
            "tools": ["Clinical Context Template"],
            "inputs": [
              {
                "name": "DTx Product Brief",
                "description": "Summary of indication, mechanism, target population.",
                "content_type": "application/pdf",
                "schema_uri": "https://schema.dhx.io/product_brief.schema.json",
                "required": true
              }
            ],
            "outputs": [
              {
                "name": "Clinical Context Document",
                "artifact_kind": "doc",
                "content_type": "application/vnd.openxmlformats-officedocument.wordprocessingml.document",
                "schema_uri": "https://schema.dhx.io/clinical_context.schema.json",
                "version": "v1.0"
              }
            ],
            "prompts": [
              {
                "name": "Clinical_Context_Definition",
                "pattern": "CoT",
                "prompt_id": "uc01_1_1_1",
                "version": "v1.0",
                "system_prompt": "You are a Chief Medical Officer defining digital therapeutic clinical context.",
                "user_template": "Define disease burden, population, and mechanism for {product_name} treating {indication}.",
                "model_config": {"model": "gpt-5", "temperature": 0.2}
              }
            ],
            "kpis": {"Context_Completeness(%)": 100}
          },
          {
            "code": "T2.1",
            "title": "Research DTx Regulatory Precedent",
            "objective": "Identify FDA-accepted endpoints in comparable DTx to inform selection.",
            "agents": ["P02_VPCLIN", "P05_REGDIR"],
            "tools": ["FDA De Novo Database", "Literature Databases"],
            "dependencies": ["T1.1"],
            "inputs": [{"name": "Clinical Context Document", "content_type": "application/docx"}],
            "outputs": [
              {
                "name": "Regulatory Precedent Analysis",
                "artifact_kind": "doc",
                "content_type": "application/pdf",
                "schema_uri": "https://schema.dhx.io/precedent_analysis.schema.json"
              }
            ],
            "prompts": [
              {
                "name": "DTx_Precedent_Analysis",
                "pattern": "RAG",
                "prompt_id": "uc01_2_1_1",
                "system_prompt": "You are a VP Clinical Development extracting FDA precedents for endpoints.",
                "user_template": "List FDA-cleared DTx similar to {indication} and summarize their primary endpoints and measurement tools."
              }
            ],
            "kpis": {"Precedents_Identified": 3}
          },
          {
            "code": "T3.1",
            "title": "Identify Primary Endpoint Candidates",
            "objective": "Generate and evaluate 2-3 strong primary endpoint options based on precedent, psychometrics, and feasibility.",
            "agents": ["P01_CMO", "P04_BIOSTAT"],
            "tools": ["Endpoint Evaluation Matrix"],
            "dependencies": ["T2.1"],
            "inputs": [
              {"name": "Regulatory Precedent Analysis", "content_type": "application/pdf"},
              {"name": "Patient Outcome Priorities", "content_type": "application/docx"}
            ],
            "outputs": [
              {"name": "Primary Endpoint Candidate Analysis", "artifact_kind": "doc", "content_type": "application/pdf"}
            ],
            "prompts": [
              {
                "name": "Primary_Endpoint_Identification",
                "pattern": "CoT",
                "prompt_id": "uc01_3_1_1",
                "system_prompt": "You are a CMO choosing primary endpoints for a DTx trial.",
                "user_template": "Compare candidate endpoints (validated PROs, clinical outcomes, digital biomarkers) for {indication}. Rate by regulatory precedent, meaningfulness, psychometrics, feasibility."
              }
            ],
            "kpis": {"Candidates_Ranked": 3}
          },
          {
            "code": "T4.1",
            "title": "Evaluate Psychometric Properties",
            "objective": "Assess reliability, validity, responsiveness, and MCID for each candidate endpoint.",
            "agents": ["P04_BIOSTAT"],
            "tools": ["Psychometric Evaluation Template"],
            "dependencies": ["T3.1"],
            "inputs": [{"name": "Endpoint Candidate List", "content_type": "application/json"}],
            "outputs": [
              {"name": "Psychometric Properties Assessment", "artifact_kind": "dataset", "content_type": "application/json"}
            ],
            "prompts": [
              {
                "name": "Psychometric_Evaluation",
                "pattern": "CoT",
                "prompt_id": "uc01_4_1_1",
                "system_prompt": "You are a Biostatistician summarizing psychometric evidence for endpoints.",
                "user_template": "For {endpoint_list}, extract reliability (α, ICC), validity, responsiveness, and MCID values from literature."
              }
            ],
            "kpis": {"Endpoints_With_MCIDs(%)": 100}
          },
          {
            "code": "T5.2",
            "title": "Final Recommendation & Stakeholder Alignment",
            "objective": "Synthesize evidence into final endpoint recommendation and prepare stakeholder materials.",
            "agents": ["P01_CMO"],
            "tools": ["Decision Matrix Template", "Presentation Deck Template"],
            "dependencies": ["T4.1"],
            "inputs": [
              {"name": "Psychometric Assessment", "content_type": "application/json"},
              {"name": "Digital Feasibility Analysis", "content_type": "application/pdf"}
            ],
            "outputs": [
              {"name": "Final Endpoint Selection Report", "artifact_kind": "doc", "content_type": "application/pdf", "version": "v1.0"},
              {"name": "Stakeholder Presentation Deck", "artifact_kind": "deck", "content_type": "application/vnd.ms-powerpoint"}
            ],
            "prompts": [
              {
                "name": "Final_Recommendation",
                "pattern": "CoT",
                "prompt_id": "uc01_5_2_2",
                "system_prompt": "You are a CMO preparing the final endpoint recommendation summary.",
                "user_template": "Summarize chosen primary and secondary endpoints with rationale, risk mitigation, and measurement schedule for {trial_name}."
              }
            ],
            "kpis": {"Stakeholder_Approval(%)": 100}
          }
        ],
        "links": [
          {"type": "use_case_dependency", "use_case_code": "UC_CD_002", "note": "Feeds into DTx Reimbursement Strategy via endpoint value evidence."}
        ]
      }
    ],
    "risk_register": [
      {"id": "R1", "title": "FDA may question PHQ-9 as primary endpoint", "probability": "MEDIUM", "impact": "HIGH", "mitigation": "Pre-Sub meeting; include HAM-D secondary.", "owner": "P05_REGDIR"},
      {"id": "R2", "title": "High patient attrition reduces data completeness", "probability": "MEDIUM", "impact": "MEDIUM", "mitigation": "Engagement reminders, incentives, flexible windows.", "owner": "P02_VPCLIN"}
    ],
    "milestones": [
      {"name": "Clinical Context Complete", "due_date": "2025-10-15", "owner": "P01_CMO", "status": "done"},
      {"name": "Pre-Sub Meeting Scheduled", "due_date": "2026-02-01", "owner": "P05_REGDIR", "status": "planned"}
    ],
    "integrations": [
      {"system": "FDA_Database", "vendor": "FDA.gov", "endpoint": "https://www.accessdata.fda.gov", "auth": "public"},
      {"system": "ClinicalTrials.gov", "vendor": "NIH", "endpoint": "https://clinicaltrials.gov/api/v2", "auth": "public"}
    ],
    "audit": {
      "created_by": "user:clinical-writer@dhx.io",
      "created_at": "2025-10-10T10:00:00Z",
      "updated_by": "user:reg-affairs@dhx.io",
      "updated_at": "2025-10-10T15:00:00Z",
      "approved_by": "user:chief-medical-officer@dhx.io",
      "approved_at": "2025-10-10T16:00:00Z"
    }
  }
}
